Tenatoprazole

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tenatoprazole
Tenatoprazole.svg
Clinical data
Routes of
administration
Oral
ATC code
  • none
Pharmacokinetic data
Metabolism Hepatic (CYP2C19-mediated)
Biological half-life 4.8 to 7.7 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard 100.120.697
Chemical and physical data
Formula C16H18N4O3S
Molar mass 346.405 g/mol
3D model (Jmol)
Chirality Racemic mixture
  (verify)

Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).[3]:22

Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[4]:27 and again in 2012.[3]:17

Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]

See also[edit]

References[edit]

  1. ^ DataMonitor. March 2003. Gastrointestinal Disease Update: Digestive Disease Week 2003
  2. ^ Economic Times. 3 March, 2011. Investors unwilling to forgive Wockhardt, promoter for failings
  3. ^ a b Mitsubishi Tanabe Pharma State of New Product Development (as of May 8, 2012)
  4. ^ Mitsubishi Tanabe Pharma FY2007 Interim Financial Results
  5. ^ Li H et al. H+/K+-ATPase inhibitors: a patent review. Expert Opin Ther Pat. 2013 Jan;23(1):99-111. PMID 23205582